Showing 1 – 8 of 8
Relevance | Newest | Oldest |
  • Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial

    Abstract Full Text
    open access has multimedia
    JAMA Cardiol. 2024; 9(4):323-334. 10.1001/jamacardio.2023.5661

    This substudy of a randomized clinical trial investigates the effects of pitavastatin on noncalcified coronary artery plaque using coronary computed tomography angiography and on inflammatory biomarkers as potential mechanisms for major adverse cardiovascular event prevention.

  • Mineralocorticoid Receptor Antagonism by Eplerenone and Arterial Inflammation in HIV: The MIRABELLA HIV Study

    Abstract Full Text
    JAMA Cardiol. 2023; 9(2):189-194. 10.1001/jamacardio.2023.4578

    This randomized clinical trial investigates if treatment with a mineralocorticoid receptor antagonist reduces arterial inflammation on 18F-fludeoxyglucose–positron emission tomography/computed tomography among persons with HIV.

  • Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

    Abstract Full Text
    open access
    ÁñÁ«ÊÓƵ Netw Open. 2021; 4(6):e2114923. 10.1001/jamanetworkopen.2021.14923

    This cohort study examines the prevalence of coronary artery disease (CAD) among adults with well-controlled HIV and low to moderate risk of atherosclerotic cardiovascular disease using computed tomography angiography and assessment of inflammation and immune activation biomarkers.

  • Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection

    Abstract Full Text
    free access
    JAMA Cardiol. 2016; 1(4):474-480. 10.1001/jamacardio.2016.0846

    This study evaluates the effects of newly initiated antiretroviral therapy (ART) on arterial inflammation and other immune/inflammatory indices in ART-naive patients with human immunodeficiency virus infection.

  • Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2014; 312(4):380-389. 10.1001/jama.2014.8334

    Stanley and coauthors conducted a randomized clinical trial among 50 antiretroviral-treated men and women with human immunodefiency virus infection (HIV) and abdominal fat accumulation to investigate the effect of the growth hormone–releasing hormone analog tesamorelin on visceral adipose tissue and liver fat.

  • Arterial Inflammation in Patients With HIV

    Abstract Full Text
    free access
    JAMA. 2012; 308(4):379-386. 10.1001/jama.2012.6698
    Subramanian and coauthors assess arterial wall inflammation in human immunodeficiency virus using 18fluorine-2-deoxy-D-glucose positron emission tomography in relationship to traditional and nontraditional risk markers, including soluble CD163. See the related Editorial by Stein and Hsue.
  • Effects of Etanercept in Patients With the Metabolic Syndrome

    Abstract Full Text
    free access
    Arch Intern Med. 2006; 166(8):902-908. 10.1001/archinte.166.8.902
  • Medical Findings in Outpatients With Anorexia Nervosa

    Abstract Full Text
    free access
    Arch Intern Med. 2005; 165(5):561-566. 10.1001/archinte.165.5.561